MEDPMedpace Holdings, Inc.

$669.27+28% 1Y

$669.27

$393.4252 weeks$669.27

Is the price fair?

Fair

Neither cheap nor expensive: nothing decisive, though modest expectations priced in.

1 good, 1 neutral, 1 without data

What the price assumes~+10% a yearderived · Sep 30, 2026

Priced for ~10% a year FCF growth. The price demands less than its three-year revenue growth of 17% a year, expectations look modest.

Vs its own P/E rangemid-range for this companyderived

In its normal range: P/E 37.2 vs a 33.1 median over 41 quarters (+12% vs median).

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 79% of the market

FCF yieldbehind 67% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

Medpace Holdings, Inc. trades at 37.2× earnings against 36.7× for the median Diagnostics & Research name, more expensive than its own group.

37.2

Trailing P/E · Diagnostics & Research median 36.7 · 1.01× the median: the market pays up for this one

Price / sales: 6.24
Price / sales · as of 2026-Q3
Free cash flow yield: 3.6%
Free cash flow yield · Diagnostics & Research median 2.9%
Growth the price implies: +10%
Growth the price implies · The price pays for +10% free cash flow growth a year for a decade; the business has delivered +21% a year over the last three.

Details›

What the market has paid for these earnings: 41 quarters of its own multiple × $18.01 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$511.83
Its own P/E history, median	$596.19
Its own P/E history, upper quartile	$687.06
52-week range	$393.42 – $669.27
Today	$669.27

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.